NEUROCRINE BIOSCIENCES INC (NBIX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 1.5B 3B 4.5B Q3 '16: 15M Q4 '16: 15M Q1 '17: 0 Q2 '17: 6.3M Q3 '17: 67.1M Q4 '17: 161.6M Q1 '18: 232.7M Q2 '18: 323.3M Q3 '18: 414.3M Q4 '18: 451.2M Q1 '19: 518.6M Q2 '19: 605.1M Q3 '19: 675.5M Q4 '19: 788.1M Q1 '20: 886.8M Q2 '20: 1B Q3 '20: 1B Q4 '20: 1B Q1 '21: 1B Q2 '21: 1B Q3 '21: 1.1B Q4 '21: 1.1B Q1 '22: 1.2B Q2 '22: 1.3B Q3 '22: 1.4B Q4 '22: 1.5B Q1 '23: 1.6B Q2 '23: 1.7B Q3 '23: 1.8B Q4 '23: 1.9B Q1 '24: 2B Q2 '24: 2.1B Q3 '24: 2.2B Q4 '24: 2.4B Q1 '25: 2.4B Q2 '25: 2.5B Q3 '25: 2.7B Q4 '25: 2.9B Q1 '26: 3.1B Q2 '26: 3.4B Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-300M 0 300M 600M 900M Q3 '15: -83.9M Q4 '15: -94.2M Q1 '16: -112.8M Q2 '16: -129.3M Q3 '16: -131.9M Q4 '16: -147.4M Q1 '17: -206.4M Q2 '17: -221.9M Q3 '17: -189.4M Q4 '17: -131.4M Q1 '18: -88.9M Q2 '18: -33.5M Q3 '18: 26.9M Q4 '18: 36.8M Q1 '19: -26.8M Q2 '19: 9.5M Q3 '19: 45.3M Q4 '19: 72.3M Q1 '20: 232.2M Q2 '20: 274.4M Q3 '20: 140M Q4 '20: 163M Q1 '21: 135.6M Q2 '21: 121.8M Q3 '21: 210.6M Q4 '22: 249M Q1 '23: 131.7M Q2 '23: 150.6M Q3 '23: 204M Q4 '23: 250.9M Q1 '24: 464.4M Q2 '24: 536.2M Q3 '24: 578.8M Q4 '24: 570.5M Q1 '25: 494.8M Q2 '25: 495M Q3 '25: 550.2M Q4 '25: 619.1M Q1 '26: 788.9M Q2 '26: 794.8M Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-250M 0 250M 500M 750M Q3 '15: -79.1M Q4 '15: -88.9M Q1 '16: -107M Q2 '16: -123.3M Q3 '16: -125.7M Q4 '16: -141.1M Q1 '17: -200.2M Q2 '17: -219.9M Q3 '17: -194.1M Q4 '17: -142.5M Q1 '18: -106M Q2 '18: -52M Q3 '18: 9.9M Q4 '18: 21.1M Q1 '19: -39.2M Q2 '19: 18M Q3 '19: 21.1M Q4 '19: 37M Q1 '20: 176.5M Q2 '20: 204.8M Q3 '20: 93.4M Q4 '20: 407.3M Q1 '21: 402M Q2 '21: 364.7M Q3 '21: 444.8M Q4 '22: 154.5M Q1 '23: 64M Q2 '23: 176.4M Q3 '23: 191M Q4 '23: 249.7M Q1 '24: 369.7M Q2 '24: 339.2M Q3 '24: 385.9M Q4 '24: 341.3M Q1 '25: 305.8M Q2 '25: 348.3M Q3 '25: 428M Q4 '25: 478.6M Q1 '26: 668.6M Q2 '26: 705.5M Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 25M 50M 75M Q1 '18: 2.2M Q2 '18: 3M Q3 '18: 4.1M Q4 '18: 4.9M Q1 '19: 5.1M Q2 '19: 5.8M Q3 '19: 6.5M Q4 '20: 10.1M Q1 '21: 10.9M Q2 '21: 11.6M Q3 '21: 13.1M Q4 '21: 14.3M Q1 '22: 16M Q2 '22: 17.7M Q3 '22: 19.6M Q4 '22: 23.2M Q1 '23: 27.1M Q2 '23: 33.8M Q3 '23: 38.9M Q4 '23: 39.7M Q1 '24: 38.7M Q2 '24: 36.4M Q3 '24: 33.2M Q4 '24: 34M Q1 '25: 35.7M Q2 '25: 37.8M Q3 '25: 43.8M Q4 '25: 52.1M Q1 '26: 56.7M Q2 '26: 68.6M Q2 '18 Q2 '19 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Cash Flow TTM

-350M 0 350M 700M 1.1B Q3 '16: -89.8M Q4 '16: -106.2M Q1 '17: -154.3M Q2 '17: -188.2M Q3 '17: -166.5M Q4 '17: -94.3M Q1 '18: -55.5M Q2 '18: 13.3M Q3 '18: 91.5M Q4 '18: 101.4M Q1 '19: 27.4M Q2 '19: 71.1M Q3 '19: 100M Q4 '19: 147M Q1 '20: 295M Q2 '20: 349.7M Q3 '20: 231.5M Q4 '20: 228.5M Q1 '21: 280.3M Q2 '21: 264.6M Q3 '21: 346.8M Q4 '21: 256.5M Q1 '22: 128.7M Q2 '22: 163.6M Q3 '22: 200.6M Q4 '22: 339.4M Q1 '23: 254.7M Q2 '23: 296.2M Q3 '23: 409.4M Q4 '23: 389.9M Q1 '24: 645.4M Q2 '24: 530.4M Q3 '24: 476.4M Q4 '24: 595.4M Q1 '25: 529.9M Q2 '25: 567.3M Q3 '25: 636.8M Q4 '25: 782.7M Q1 '26: 863.7M Q2 '26: 898.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-250M 0 250M 500M 750M Q4 '15: -39.9M Q1 '16: -51.4M Q2 '16: -81.4M Q3 '16: -94.3M Q4 '16: -110.3M Q1 '17: -159.1M Q2 '17: -191.1M Q3 '17: -171.4M Q4 '17: -101.3M Q1 '18: -62.8M Q2 '18: 1.6M Q3 '18: 70.3M Q4 '18: 76.6M Q1 '19: 486K Q2 '19: 44.4M Q3 '19: 82.1M Q4 '19: 132.3M Q1 '20: 282.9M Q2 '20: 337.4M Q3 '20: 222.3M Q4 '20: 217.6M Q1 '21: 266.2M Q2 '21: 250.9M Q3 '21: 327.8M Q4 '21: 233.1M Q1 '22: 102.2M Q2 '22: 132.6M Q3 '22: 177M Q4 '22: 322.9M Q1 '23: 237.3M Q2 '23: 280.8M Q3 '23: 384.7M Q4 '23: 361.6M Q1 '24: 614.4M Q2 '24: 494.6M Q3 '24: 440.1M Q4 '24: 557.2M Q1 '25: 492.2M Q2 '25: 528.7M Q3 '25: 593.1M Q4 '16 Q1 '18 Q2 '19 Q3 '20 Q4 '21 Q1 '23 Q2 '24 Q3 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q2 '12: 66.3M Q3 '12: 66.3M Q4 '12: 67.7M Q1 '13: 66.6M Q2 '13: 66.8M Q3 '13: 67.2M Q4 '13: 67.3M Q1 '17: 87.3M Q2 '17: 88.1M Q3 '17: 88.3M Q4 '17: 92.7M Q1 '18: 89.5M Q2 '18: 90.1M Q3 '18: 96.8M Q4 '18: 95.7M Q1 '19: 91.1M Q2 '19: 94.8M Q3 '19: 96.1M Q4 '19: 97.2M Q1 '20: 97M Q2 '20: 98.2M Q3 '20: 93.3M Q4 '20: 97.2M Q1 '21: 98.2M Q2 '21: 97.7M Q3 '21: 97.7M Q1 '22: 97.6M Q2 '22: 95.6M Q3 '22: 99M Q1 '23: 97.1M Q2 '23: 100.2M Q3 '23: 101.1M Q1 '24: 103.6M Q2 '24: 103.9M Q3 '24: 104.3M Q1 '25: 102.5M Q2 '25: 101M Q3 '25: 102.5M Q1 '26: 103.4M Q2 '26: 104.2M Q2 '13 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-5.00 -2.50 0.00 2.50 5.00 7.50 Q3 '15: -0.95 Q4 '15: -1.03 Q1 '16: -1.24 Q2 '16: -1.42 Q3 '16: -1.45 Q4 '16: -1.62 Q1 '17: -2.30 Q2 '17: -2.52 Q3 '17: -2.22 Q4 '17: -1.64 Q1 '18: -1.21 Q2 '18: -0.60 Q3 '18: 0.05 Q4 '18: 0.17 Q1 '19: -0.48 Q2 '19: 0.13 Q3 '19: 0.17 Q4 '19: 0.33 Q1 '20: 1.84 Q2 '20: 2.11 Q3 '20: 0.93 Q4 '20: 4.16 Q1 '21: 4.10 Q2 '21: 3.72 Q3 '21: 4.57 Q4 '22: 1.54 Q1 '23: 0.61 Q2 '23: 1.74 Q3 '23: 1.87 Q4 '23: 2.44 Q1 '24: 3.65 Q2 '24: 3.33 Q3 '24: 3.75 Q4 '24: 3.29 Q1 '25: 2.95 Q2 '25: 3.38 Q3 '25: 4.18 Q4 '25: 4.66 Q1 '26: 6.49 Q2 '26: 6.82 Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.